Greg J. Slater

Learn More
Advanced metastatic melanoma is incurable by standard treatments, but occasionally responds to immunotherapy. Recent trials using dendritic cells (DC) as a cellular adjuvant have concentrated on defined peptides as the source of antigens, and rely on foreign proteins as a source of help to generate a cell-mediated immune response. This approach limits(More)
OBJECTIVE AMI-227 is an ultrasmall superparamagnetic iron oxide colloid known to enhance tissue T1 and T2 relaxation rates. Animal studies show that AMI-227 has an estimated blood half-life of more than 200 min. In this study, we evaluated the clinical utility of AMI-227 as an MR contrast agent for detection and characterization of focal hepatic lesions,(More)
OBJECTIVE We evaluated sonographic abnormalities of the gallbladder other than acalculous cholecystitis across a broad range of intensive care unit (ICU) patients. SUBJECTS AND METHODS Fifty-five consecutive patients (age range, 18-94 years old; mean age, 56 years; 33 men, 22 women), who were admitted to the ICU with a variety of diagnoses, underwent(More)
The potential of ultrasmall superparamagnetic iron oxide (Combidex)-enhanced MRI of pelvic lymph nodes in patients with primary pelvic carcinoma is evaluated. Fifteen histologically classified lymph nodes in six patients with known primary pelvic cancer (four prostate; one rectum; one uterus) were evaluated with T2-weighted fast spin-echo (FSE) and(More)
OBJECTIVE The purpose of this study was to evaluate pancreatic enhancement with low-dose mangafodipir trisodium (5 mumol/kg) using three different T1-weighted pulse sequences. SUBJECTS AND METHODS Fifteen patients, six of whom had proven focal pancreatic tumors, underwent T1-weighted gradient-recalled echo imaging, spin-echo imaging, and fat-suppressed(More)
OBJECTIVE The purpose of this study were to quantify abdominal vascular enhancement and to prove the feasibility of iron oxide-enhanced MR angiography in humans using three doses of superparamagnetic iron oxide agent AMI 227. SUBJECTS AND METHODS Sixteen patients randomly received either 0.8, 1.1, or 1.7 mg Fe/kg of ultrasmall superparamagnetic iron oxide(More)
PURPOSE To determine prospectively the safety and efficacy of the blood-pool contrast agent gadofosveset trisodium in renal artery magnetic resonance angiography (MRA). MATERIALS AND METHODS Gadofosveset (0.03 mmol/kg) was administered to adult patients with known or suspected renal arterial disease in a multi-center phase 3 single dose study. The drug(More)
AIM To compare liver enhancement and lesion-liver contrast on T1-weighted (T1W) gradient recalled echo (GRE), spin-echo (SE) and fat-suppressed SE (FS-SE) pulse sequences at Manganese-DPDP (Mn-DPDP) enhanced magnetic resonance (MR) imaging of the liver. PATIENTS AND METHODS. Twenty-one patients with known liver lesions were administered 5 mumol/kg of(More)
  • 1